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Background: The PHQ-15 is widely used as an open access screening instrument for somatization syndromes in
different health care settings, thus far, normative data from the general population are not available. The objectives
of the study were to generate normative data and to further investigate the construct validity of the PHQ-15 in the
general population.
Methods: Nationally representative face-to face household surveys were conducted in Germany between 2003 and
2008 (n=5,031). The survey questionnaires included, the 15-item somatization module from the Patient Health
Questionnaire (PHQ-15), the 9-item depression module (PHQ-9), the Satisfaction With Life Scale (SWLS), the SF-12
for the measurement of health related quality of life, and demographic characteristics.
Results: Normative data for the PHQ-15 were generated for both genders and different age levels including 5031
subjects (53.6% female) with a mean age (SD) of 48.9 (18.1) years. Somatization syndromes occured in 9.3% of the
general population. Women had significantly higher mean (SD) scores compared with men [4.3 (4.1) vs. 3.4 (4.0)].
Intercorrelations with somatization were highest with depression, followed by the physical component summary
scale of health related quality of life.
Conclusions: The normative data provide a framework for the interpretation and comparisons of somatization
syndromes with other populations. Evidence supports reliability and validity of the PHQ-15 as a measure of
somatization syndromes in the general population.
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Somatization is one of the most common issues in
health care services, associated with substantial func-
tional impairment and health care utilization [1-3]. Their
valid and reliable acquisition is urgently necessary.
Somatoform symptoms often account for sick leave and
are characterized by long duration and medically unex-
plained symptoms [4-7]. The most frequently reported
symptoms are fatigue, low energy, sleeping trouble, and
pain (back pain, headaches, abdominal pain, and chest
pain) [8,9]. Medically unexplained symptoms are one of
the key features of somatoform disorders. Although they* Correspondence: r.kocalevent@uke.de
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distribution, and reproduction in any mediumare currently treated as both categorical (in terms of the
diagnosis of somatoform disorders) and dimensional (in
terms of quantitative measures of somatization/somatic
symptom reporting), little is known about the empirical
latent structure of medically unexplained symptoms. Ac-
cordingly to recent study results, the latent structure of
somatization/somatic symptom reporting as assessed by
the PHQ-15 is dimensional in both primary care and
student samples [10].
Estimated prevalence rates of undifferentiated soma-
toform disorders vary between 8.6%-25.6% in primary care,
depending on the chosen screening instrument and
whether pain is taken into account or not [8,11-13]. Recent
reported data on somatoform symptom clusters in the gen-
eral population are still scarce [14]. Wittchen and col-
leagues (2011) reported in their systematic review atral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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the EU with little evidence for considerable cultural or
country variation [15]. 4-week, 12-month and lifetime
prevalence rates of any somatoform disorder in the
German general population was reported with 7.5%, 11.0%,
and respectively 16.2% [16].
Most clinicians nowadays evaluate, whether or not the
reported somatoform complaints are associated with dis-
tress and psychological impairment, both predictors for
somatoform disorders [17]. Screening instruments can
add valuable diagnostic information, yet they vary con-
siderably in length and diagnostic focus (for an overview
of measures used in clinical trials of somatoform disor-
ders see [18]). Patients often complain about the amount
of items, which can lead to a difficult doctor-patient re-
lationship and lower self-perception of quality of life and
life satisfaction [1,19-21]. The reported impairment of
every day functioning can be even higher when the pa-
tients are affected by comorbid conditions as depression
and/or anxiety, which occurs in up to 43% with increas-
ing number of physical symptoms [11,17,22]. A difficult
encounter, as perceived by the clinician, may be another
predictor of psychiatric comorbidity in patients who
have somatoform symptoms [22]. The collaboration be-
tween patients and their doctors might also carry the
risk of shaping, reinforcing, and legitimizing somatoform
syndromes [23]. Hence it is important to take standard-
ized assessment of somatization into account. These
measures can have a variety of uses, including screening,
early pre-diagnosis, assessment of severity, and gauging
treatment decisions of both clinicians and patients.
The PHQ-15 is a self-administered somatic symptoms
subscale, derived from the full Patient-Health-Questionnaire
[7,24]. Relatively brief, it screens for 15 somatic symp-
toms that account for more than 90% of the physical
complaints reported in the outpatient setting (exclusive
of self-limited upper respiratory symptoms) [20]. The
PHQ-15 is a valid measure, which has been used in 40
studies so far in different health care settings (for an
overview see [11]). Valid and reliable measures for the
assessment of somatic symptoms, as the PHQ-15, have
been used in psychiatric research and routinely in clin-
ical practice so far (i.e. primary care). Normative data,
which could be used to compare a subject's scale score
with those determined from a general population refer-
ence group, are still scarce and restraint to relative risk
factors [25]. The obtained findings could be further uti-
lized as reference categories in community studies and
open-access web-based screening tools [15,26,27].
In this study we provide normative data for the PHQ-
15 for different age groups and both genders. In addition
we address the relations of somatic symptoms with
depression, and quality of life and life satisfaction to pro-
vide further evidence for the construct validity in ageneral population. According to previous results, we
expect that higher PHQ-15 scores will be associated with
worsening quality of life and life satisfaction as well as
with increased depression [11].Methods
Study sample
Nationally representative face-to face household surveys
were conducted in Germany between 2003 and 2008
(n=5,031), representative of the German general popula-
tion, with the assistance of an institute specialized for
demographic research (USUMA, Berlin) according to
the German law of data protection (§30a BDSG) and
with written consent. Previously ethics were weighted to
the respective interests of the public and of the individ-
uals concerned following §823 (BGB) of the Civil Code
of Law and in accordance with the guidelines in the
Declaration of Helsinki. Representativeness was assured
through a weighting process. Age, gender, and educa-
tional level were the major criteria for representativeness
according to the register of the Federal Elections. Two
callbacks had to be without success before an address was
considered a failure. The sampling procedure consisted of
sample points, household, and persons in the last stage.
Target households within the sample points were deter-
mined using the random-route procedure: choosing sam-
ple point areas within Germany, randomly choosing
households within these areas, and randomly choosing tar-
get persons within these households.Sample characteristics
Attempts were made to contact 8008 persons. The set of
questionnaires was administered to a sample of 5031
persons. Therefore the response rate was 62.8%. The
main reasons for non-participation (37.2%) were: the
general information request was refused (15.8%), the
interview request was refused (7.9%), or there was no
one at home for three times in a row (7.3%).
Sociodemographic characteristics of the sample are
reported in Table 1. The analysis of the distribution of the
data yielded skewness and kurtosis values of somatization
of 1.63 and 3.29, respectively. We therefore decided to in-
vestigate group differences for sociodemographic charac-
teristics using non-parametric tests.
There were significant gender, age, education level,
employment status, and income effects in the general
population associated with a higher PHQ-15 score. The
most marked group and the lowest groups were consid-
ered calculating the value of Cohen’s d using the means
and standard deviations. As noted in Table 1, the calcu-
lated effect sizes were moderate for income and educa-
tion, and high for age. Gender and employment status
yielded small effect sizes.
Table 1 Demographic characteristics of the study sample and associations with PHQ-15 scores (N=5,031)
N (%) PHQ-15 score M (SD) Group differencesa p-value Cohen’s d, effect-size
Gender χ2(28)=144.5; p<0.001 d=0.22
Male 2332 (46.4) 3.4 (4.0)
Female 2699 (53.6) 4.3 (4.1)
Age group, yr χ2(6)=425.1; p<0.001 d=0.91
14-24 564 (11.2) 2.4 (3.5)
25-34 630 (12.5) 2.8 (3.5)
35-44 938 (18.6) 3.2 (3.7)
45-54 871 (17.3) 3.6 (3.8)
55-64 844 (16.8) 4.5 (4.1)
65-74 792 (15.7) 4.8 (4.2)
≥ 75 392 (7.8) 6.3 (4.9)
Living with a partner χ2(28)=34.5; p=0.75 -
Yes 2927 (58.3) 3.8 (3.9)
No 2092 (41.7) 4.0 (4.2)
Education χ2(4)=123.3; p<0.001 d=0.74
None 91 (1.8) 5.1 (4.5)
Highschool 3878 (77.3) 3.9 (3.9)
College 525 (10.5) 3.7 (4.0)
University 344 (6.9) 3.3 (3.3)
Currently student 181 (3.6) 2.2 (3.2)
Unemployment
Yes 297 (5.9) 4.3 (4.2) χ2(28)=52.4; p=0.003 d=0.12
No 4722 (94.1) 3.8 (4.1)
Net household incomeb
<1250 € / mo 1301 (27.3) 4.8 (4.4) χ2(2)=143.2; p<0.001 d=0.45
1250-<2500 € / mo 2499 (52.5) 3.7 (3.9)
≥ 2500 € / mo 964 (20.2) 2.9 (4.0)
a Group differences were performed using χ2-test and Kruskal-Wallis-test (p<0.001).
b USD$1=EUR€0.77.
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Somatization (PHQ-15)
Somatization was measured using the somatic symptom
module of the PHQ, the PHQ-15 [7,28]. The items include
the most prevalent DSM-IV somatization disorder somatic
symptoms [29]. Subjects were asked for the last 4 weeks to
rate the severity of 13 symptoms as 0 (“not bothered at all”),
1 (“bothered a little”), or 2 (“bothered a lot”). Two additional
physical symptoms - feeling tired or having little energy,
and trouble sleeping – are contained in the PHQ-9 depres-
sion module. For scoring, response options for these two
symptoms are coded as 0 (“not at all”), 1 (“several days”), or
2 (“more than half the days” or “nearly every day”).
Thus, the total PHQ-15 score ranges from 0 to 30 and
scores of ≥5, ≥10, ≥15 represent mild, moderate and se-
vere levels of somatization. The reliability and validity of
the PHQ-15 are high in clinical and occupational health
care settings [2,7,11].Depression (PHQ-9)
Depression was assessed with the PHQ nine item de-
pression module (PHQ-9) [30]. Each of the nine PHQ
depression items corresponds to one of the DSM-IV
Diagnostic Criterion A symptoms for major depressive
disorder [29]. Subjects were asked how often, over the
last two weeks, they have been bothered by each of the
depressive symptoms. Response options are “not at all”,
“several days”, “more than half the days”, and “nearly
every day”, scored as 0, 1, 2 and 3, respectively. PHQ-9
scores range from 0 to 27, with scores of ≥5, ≥10, ≥15,
representing mild, moderate and severe levels of depres-
sion severity [31]. Psychometric properties of the PHQ-9
are well documented (for an overview see [11]).
Quality of life (SF-12)
The SF-12 is an ubiquitary adopted generic question-
naire on the subjectively perceived health-related quality
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of adults for different diseases, in relation to their phys-
ical, psychological, and social aspects [32]. A longer ver-
sion of the SF-12, the SF-20, was already previously used
to assess functional impairment in combination with the
PHQ-15 [7,17].
SF-12 scales are namely: general health, physical func-
tioning, role physical, bodily pain, vitality, social func-
tioning, mental health, role emotional, yielding the
summary scales physical- and mental health.
Life satisfaction (SWLS)
Satisfaction with life was measured with the Satisfaction
With Life Scale, designed to measure global cognitive
judgments of satisfaction with one's life, and consists of
five items [33,34]: “In most ways my life is close to my
ideal”, “The conditions of my life are excellent”, “I am
satisfied with my life”, “So far I have gotten the import-
ant things I want in life”, and “If I could live my life over,
I would change almost nothing”.
Respondents indicated the extent to which they agreed
with each item on a seven-point Likert scale ranging
from “strongly agree” to “strongly disagree”. Translations
of the SWLS into various languages are available and
psychometric properties have been reviewed [35].
Internal consistencies
The parameter of internal consistency (Cronbach’s α) for
the PHQ15 scale reached the value of α =0.82, for the
PHQ-9 α=0.88 respectively. The Satisfaction with Life
Scale showed a very good Cronbach’s α of 0.91. Cronbach’s
α for the mental component scale (MCS) was 0.84, 0.91
respectively for the physical component scale (PCS) of the
SF-12.
Data analysis
For reliability, internal consistency of the PHQ-15 was
assessed. Base rates for single symptoms were calculated
using frequency analysis. Descriptive statistics included
analyses of prevalence. To determine prevalence rates, a
cut-off score of ≥10 was used on the PHQ-15 because
the range of ≥10 up to 30 reflects medium and high
somatic symptom severity, respectively [7]. The selection
of this cut-off score resulted in previous studies in a sen-
sitivity of 80.2% und specifity of 58.5% for a somatoform
disorder [3]. For construct validity, we investigated
PHQ-15 scale intercorrelations with the PHQ-9 [7,30],
the SF-12 [32], and the Satisfaction With Life Scale
[33]. In addition, we investigated group differences
for sociodemographic characteristics using χ2-test and
Kruskal-Wallis-test, respectively. Based on results from
previous studies with the PHQ-15, we expected that
women would have higher somatization scores com-
pared with men and that levels of somatization increasewith age and lower levels of education [8]. To provide
normative data for the PHQ-15, we generated age- and
gender specific percentiles for the PHQ-15 total score.
Sample size was sufficient to be divided into gender-
specific age groups comprising 10 years each. Statistical
analyses were conducted using SPSS with an α-level of
1%. According to previous other studies with the PHQ-
15 [11,17], missing values were replaced with the mean
value of the remaining items if the number of missing
items was below 20%. If the number of missing items in
the scale exceeded 20%, the sum score was not com-
puted and counted as missing.
Results
Prevalence of somatization syndromes
By using the cut-off scores described below, the total
prevalence of somatization syndromes at a moderate to
high level was estimated to be 9.3%; 8.1% of the men
and 10.3% of women had a PHQ-15 sum score ≥10.
Base rates of single symptoms
The gender-stratified prevalence rates of the individual
symptoms are shown in Figure 1. The most common
symptoms were various types of pain (back pain, head-
ache, pain of the joints and extremities) with prevalence
rates >35%, if symptom reporting of any degree of sever-
ity was considered for both genders. Highest rates for se-
vere symptom rating were found for the same symptoms
(>4%). Further 2.4% of the total sample complained
about sleeping trouble and 1.4% of a lack of energy
nearly every day.
Construct validity
The intercorrelations between the PHQ-15 total score
and the PHQ-9 depression scale, the SF-12 for the as-
sessment of quality of life (physical and mental factor),
and the Satisfaction with Life Scale are summarized in
Table 2. Intercorrelations with somatization were highest
with depression (r=0.75 p<0.001), followed by the phys-
ical component summary scale of health related quality
of life (r=−0.64 p<0.001), and the subscale “bodily pain”
respectively (r=−0.68 p<0,001). Intercorrelation of de-
pression was higher with the mental component summary
scale of health related quality of life (r=−0.68 p<0.001)
than the physical component (r=−0.48 p<0,001) compared
to somatization. Two items, “feeling tired or having little
energy” and “trouble falling asleep, or sleeping too much”
represent shared questions between the PHQ-9 and the
PHQ-15. Omitted from the somatization scale, the inter-
correlation reduced from 0.75 to 0.65 (p<0.001).
Both somatization and depression were significantly
related to life satisfaction.
The associations of the PHQ-15 scores with demo-
graphic characteristics are shown in Table 1. As
Figure 1 Gender-stratified base rates of somatoform symptoms. Symptoms for which the subject had been “bothered a lot” are indicated
by the black part of the bar and defined as severe.
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women exhibited higher scores than men. Also in accord-
ance with the hypotheses, scores for somatization syn-
dromes were higher in subjects with lower educational
levels compared to subjects with higher educational levels.
No differences were found in terms of relationship or em-
ployment status.
Normative data
Table 3 summarizes the normative data for the different
age levels and both genders. Percentiles from this table
can be used to compare an individual subject’s PHQ-15Table 2 Intercorrelations of somatization, depression, life





Depression (PHQ-9) .75**a -
Life satisfaction (SWLS) -.37** -.42**
Health related quality of life
(SF-12)
Physical functioning -.61** -.50**
Role physical -.66** -.58**
Bodily Pain -.68** -.57**
General health -.62** -.52**
Vitality -.53** -.52**
Social functioning -.56** -.60**
Role Emotional -.58** -.59**







a ** p<0.001.score with those determined from the general popula-
tion reference group based on age and gender.
For example, a PHQ-15 score of 11 in a 30-year-old
man indicates a percentile rank of 93.4% in the total
population and of 98.9% in a group of subjects of the
same age and gender. Likewise, a PHQ-15 score of 11 in
a 30-year-old woman corresponds to a percentile rank of
93.4% in the total population and of 94.9% in the same
age and gender group.
Discussion
A main result of this study was the standardization of
the PHQ-15 with the provision of normative data from
the general population. Given that age and gender spe-
cific comparative data were generated based on sub-
groups consisting of n=156 to 542 subjects each, the
sample sizes were sufficient to provide normative data.
Results of a standardization study of the Patient Health
Questionnaire-4 (PHQ-4) on depression and anxiety,
yielded that the German general population could be
considered comparable to the American general popula-
tion [36]. The prevalence rate of 9.3% for somatization
syndromes corresponds to previous results of surveys in
the general population reporting on any somatoform
disorder [16] and can be considered for further explor-
ation for the presence of the spectrum of subclinical to
full somatoform disorder in clinical practice [3,7]. Previ-
ous studies in the general population on base rates for
somatoform symptoms report similar frequencies and
dominance of various types of pain [9,14]. In primary
care the different pain symptoms are also the most
prominent ones, accompanied by “lack of energy” and
“trouble sleeping” as an indicator of exacerbation [8].
The present study, including more than 5000 subjects,
gives evidence that the PHQ-15 is not only a reliable
Table 3 Normative data from the general population for the PHQ-15
Total Men Women
14-92 yr 14-24 25-34 35-44 45-54 55-64 65-74 ≥75 14-24 25-34 35-44 45-54 55-64 65-74 ≥75
N=5,031 N=292 N=279 N=396 N=414 N=398 N=397 N=156 N=272 N=351 N=542 N=457 N=446 N=395 N=236
M 3.8 1.8 2.0 2.6 3.3 4.3 4.4 5.8 3.2 3.5 3.7 3.8 4.7 5.2 6.5
SD 4.1 3.0 2.8 3.6 3.7 4.1 4.3 5.2 3.8 3.7 3.8 3.8 4.1 4.1 4.7
Sum Percentilea
Score
0 11.1 0.3 0.4 0.3 0.2 0.3 0.3 0.6 0.4 0.3 0.2 0.2 0.3 0.3 0.4
1 28.7 51.0 38.6 31.2 27.1 16.9 17.7 14.1 30.9 23.9 19.8 19.5 10.1 18.8 4.3
2 41.3 67.5 58.8 47.5 41.2 28.0 30.3 23.1 48.5 36.2 32.9 33.7 18.7 29.2 10.2
3 52.5 77.4 73.6 64.0 53.8 41.2 40.4 32.1 56.6 51.3 48.1 46.8 28.8 39.1 18.7
4 62.1 83.6 81.9 74.6 63.2 52.5 51.5 42.3 67.3 60.4 58.4 57.5 39.2 50.5 29.4
5 70.8 88.0 88.8 84.0 72.6 61.9 59.6 48.7 73.2 68.7 69.9 66.7 50.7 60.7 39.6
6 77.8 90.8 93.5 89.3 80.9 71.5 70.2 56.4 80.1 79.5 78.0 74.0 60.9 70.8 50.2
7 82.4 92.8 94.2 91.9 85.5 78.3 78.0 62.2 84.6 86.0 83.4 80.7 69.7 75.9 60.9
8 85.9 93.2 94.6 92.6 88.4 81.1 80.8 66.7 86.4 89.7 86.9 85.3 75.9 79.7 68.1
9 89.2 94.2 96.4 93.9 90.1 86.1 83.8 74.4 90.8 92.6 90.0 90.2 81.2 84.5 75.7
10 91.7 96.9 97.1 95.4 93.5 89.9 87.6 80.1 93.8 93.4 92.6 92.3 85.3 89.3 79.6
11 93.4 96.9 98.9 96.4 94.9 93.2 89.4 82.7 94.1 94.9 94.3 93.7 88.6 91.4 83.4
12 94.7 97.6 98.9 96.4 96.1 94.2 92.4 86.5 96.0 96.6 95.6 95.4 90.5 93.1 85.1
13 95.9 98.3 98.9 96.7 97.1 95.5 93.6 89.7 96.7 97.2 96.3 96.5 92.7 95.7 88.5
14 97.0 99.3 98.9 97.7 98.1 96.7 95.7 92.3 97.4 97.7 97.6 98.0 94.4 97.0 90.6
15 97.7 99.7 98.9 98.0 98.5 97.2 96.5 94.9 98.2 97.7 98.7 98.5 96.0 98.2 92.8
16 98.2 99.9 98.9 98.7 98.8 98.2 97.0 94.9 98.9 98.3 98.9 98.7 97.1 98.2 95.3
17 98.6 99.9 99.3 98.7 99.0 98.2 97.7 94.9 98.9 98.6 99.1 98.7 98.1 99.5 96.2
18 98.9 99.9 99.6 99.2 99.3 98.5 98.7 95.5 98.9 98.6 99.1 99.1 98.5 99.7 97.0
19 99.2 99.9 99.6 99.2 99.5 98.7 98.7 95.5 99.6 99.4 99.4 99.3 98.5 99.9 97.4
20 99.5 99.9 99.9 99.2 99.5 99.2 98.7 96.2 99.9 99.7 99.4 99.3 99.3 99.9 98.3
21 99.7 99.9 99.9 99.2 99.8 99.9 99.7 98.1 99.9 99.7 96.6 99.3 99.3 99.9 98.7
22 99.8 99.9 99.9 99.2 99.8 99.9 99.7 98.7 99.9 99.7 99.8 99.3 99.3 99.9 98.7
23 99.8 99.9 99.9 99.2 99.8 99.9 99.9 98.7 99.9 99.7 99.8 99.3 99.3 99.9 99.6
24 99.9 99.9 99.9 99.2 99.9 99.9 99.9 99.9 99.9 99.7 99.8 99.3 99.3 99.9 99.9
25 99.9 99.9 99.9 99.7 99.9 99.9 99.9 99.9 99.9 99.7 99.8 99.3 99.9 99.9 99.9
26 99.9 99.9 99.9 99.7 99.9 99.9 99.9 99.9 99.9 99.9 99.8 99.9 99.9 99.9 99.9
27 99.9 99.9 99.9 99.7 99.9 99.9 99.9 99.9 99.9 99.9 99.9 99.9 99.9 99.9 99.9
28 99.9 99.9 99.9 99.9 99.9 99.9 99.9 99.9 99.9 99.9 99.9 99.9 99.9 99.9 99.9
29 99.9 99.9 99.9 99.9 99.9 99.9 99.9 99.9 99.9 99.9 99.9 99.9 99.9 99.9 99.9
30 99.9 99.9 99.9 99.9 99.9 99.9 99.9 99.9 99.9 99.9 99.9 99.9 99.9 99.9 99.9
a Percentiles indicate the rank of the subject compared to other subjects of the same age group and gender.
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care settings but also in the general population. Specific-
ally, the intercorrelations of the PHQ-15 with the PHQ-
9 depression scale (r = 0.65-0.75), the SF-12 quality of
life scale (r = −0.53-0.68), and the life satisfaction scale
(r = −0.37) are similar to intercorrelations between these
concepts in other studies suggesting further constructvalidity of the PHQ-15 [11]. In the original PHQ-15 val-
idation study, which comprised of 6,000 unselected
primary care patients, higher PHQ-15 scores were also
strongly associated with worsening function on all six
SF-20 scales - a longer version of the SF-12 used in the
present study -, as well as increased disability days and
health care utilization [7,17]. The impact on the physi-
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somatization than for depression. The expressed mental
component scale showed higher associations with de-
pression than somatization. The high association of
somatization and depression in the present study might
be partly explained by the overlap of two items in the
PHQ-15 and PHQ-9 (“lack of energy”, “sleep disturb-
ance”). Yet these results of concurrent validity are sup-
ported by a former study of the PHQ-15 in relation to
depression and general mental health [37]. The comor-
bidity of somatic, anxiety and depressive symptoms
(the “SAD” triad) is well-established [11,20]. Still the
concordance could not be found in immunological pa-
rameters, where results suggest different immune alter-
ations in somatization syndrome and depression [38].
What is known, is that physiological activity (i.e. heart
rate, tension) is high in patients with somatization and
may interact with psychological processes [39].
The controverse discussion on the classifying of soma-
toform disorders, respectively syndromes, would have
gone beyond the purpose of this study (for an overview
see [18]). Although the PHQ-15 does not explicitly ask
for “medically unexplained symptoms”, it is highly asso-
ciated with clinician-rated somatoform disorder symp-
tom counts [40].
Yet a potential limitation of this general population
study is that it did not include standard criterion inter-
views, which would have allowed for calculating specificity
and sensitivity for optimal cut point and construction of a
receiver operating characteristic (ROC). The sensitivity
and specificity of the PHQ-15, as measured by the con-
cordance with the SCID-I diagnosis of somatoform disor-
ders, has previously been established as 78% and 71%,
respectively, in primary care [41]. Another limitation
might be that normative data were not reported according
to the socioeconomic status.
Reviews have identified effective behavioural and
pharmacological interventions for somatoform disorders
[42-45], and guidelines are close to be published (e.g.
S3-guideline). Reported “green flags” or prognostic fac-
tors are so far: (a) proactive coping strategies of the pa-
tient, e.g. optimism, motivation for psychotherapy; (b)
healthy lifestyle, e.g. balanced diet, relaxation, exercis-
ing, and enough sleep; (c) social support; and (d) a
good doctor-patient relationship with shared decision
making.
Reducing the burdens and enhancing early detection
of mental disorders in general requires major shifts in
research, clinical practice, and public health by incorpor-
ating multidisciplinary models of intervention. The good
news is that such changes are under way, as reflected,
for example by the experts drafting Research Roadmaps
(see www.roamer-mh.org) for the European Union and
the U.S. (see www.nihpromis.org).Conclusions
Somatization is one of the most common issues in health
care services, associated with substantial functional im-
pairment and health care utilization. Somatization syn-
dromes occur in 9.3% of the general population. Thus
validate acquisition of somatoform symptoms is necessary
in several health care settings. The PHQ-15 is a good basis
for this task. Normative data for the PHQ-15 in the gen-
eral population were generated for both genders and dif-
ferent age levels and can be used for the interpretation
and comparisons with other populations.
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